[G23-20] Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31
Last updated 05.10.2023
Project no.:
G23-20
Commission:
Commission awarded on 09.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A23-29 | Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-31 | Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-84 | Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31 | Commission completed |
Federal Joint Committee (G-BA)
05-10-2023 A G-BA decision was published.
G-BA documents on this decision